Clinical observations of high-flow nasal cannula oxygenation in endobronchial ultrasound-guided transbronchial needle aspiration: a randomized controlled study

Fangli Yue, Xinyuan Shi, Huan Zhang, Shui Yu, Min Fu, Yaxin Wei, Hongyi Xiao, Yuanyuan Zhong, Fanceng Ji, Peihe NieFrontiers in Medicine 2025 · DOI

This randomized controlled study, published in Frontiers in Medicine, demonstrates that high-flow nasal cannula (HFNC) oxygenation significantly outperforms traditional nasopharyngeal tubes (NPT) in preventing hypoxia during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). By providing stable oxygen concentrations and mild positive airway pressure, HFNC reduced the incidence of hypoxia from 25% to just 4.9%, while also improving carbon dioxide clearance.

What Problem Does This Paper Address?

EBUS-TBNA is a critical diagnostic tool for lung diseases, but it presents a significant anesthetic challenge. Because the procedure involves inserting a relatively thick bronchoscope (6.9–7.4 mm) into the airway to perform needle aspirations, it requires deep sedation to manage patient discomfort and cough.

The combination of deep sedation (which depresses breathing) and a large scope (which increases airway resistance) creates a perfect storm for hypoxia. Previous studies have shown hypoxia rates as high as 29–56% using standard oxygenation methods like nasal catheters or masks. The authors sought to determine if HFNC—a system that delivers heated, humidified oxygen at very high flow rates—could provide a safer alternative to the commonly used nasopharyngeal tube (NPT).

Methods

The researchers conducted a randomized controlled trial involving 81 patients at Weifang People’s Hospital. Patients were split into two groups:

  • HFNC Group (n=41): Received oxygen at a flow rate of 45 L/min (100% $FiO_2$) at 37°C.
  • NPT Group (n=40): Received oxygen via a 6.0 mm internal diameter nasopharyngeal tube at a standard flow rate of 6 L/min.

Both groups underwent deep sedation using target-controlled infusions (TCI) of propofol and alfentanil. The primary metric was the incidence of hypoxia, defined as $SpO_2 < 90\%$ for at least 10 seconds. The researchers also tracked "rescue" interventions (like jaw lifting or mask ventilation), arterial blood gas levels ($PaO_2$ and $PaCO_2$), and surgeon satisfaction.

Datasets

As a clinical trial, the "dataset" consisted of the 81 enrolled patients. The cohort was restricted to patients with a "healthy" BMI (18.5–28 $kg/m^2$) and excluded those with pre-existing respiratory conditions like asthma or OSAHS to minimize confounding variables.

Key Insights and Ideas

  • PEEP and Dead Space: The success of HFNC isn't just about "more oxygen." The high flow rates create a small amount of positive end-expiratory pressure (PEEP), which helps keep the small airways open. Additionally, the constant flow flushes out $CO_2$ from the upper airway's anatomical dead space.
  • The "Apneic Oxygenation" Advantage: HFNC is known to prolong "safe apnea time." In a procedure where the scope itself partially obstructs the airway, this extra buffer is vital.
  • Procedural Efficiency: In the NPT group, 17.5% of patients required mask-assisted ventilation, which requires the clinician to stop the procedure. In the HFNC group, zero patients required mask ventilation. This led to significantly higher satisfaction scores from the performing endoscopists.
  • $CO_2$ Management: While both groups showed some $CO_2$ accumulation (common in deep sedation), the HFNC group had significantly lower $PaCO_2$ levels during the procedure, suggesting better alveolar ventilation despite the sedation.

Key Results

  • Hypoxia Incidence: The HFNC group saw a massive reduction in hypoxia compared to the NPT group (4.9% vs. 25.0%, $P = 0.011$).
  • Oxygenation Quality: At the 10-minute mark (T3), the $PaO_2$ in the HFNC group was nearly double that of the NPT group (250.30 mmHg vs. 146.15 mmHg, $P < 0.001$).
  • Intervention Rates: The need for manual airway maneuvers (jaw lifting) was significantly lower in the HFNC group (4.9% vs. 25.0%).
  • Safety: There were no significant differences in adverse events like coughing or arrhythmia between the two groups, suggesting HFNC is as safe as it is effective.

Limitations and Future Work

The authors acknowledge two primary limitations:

  1. Single-Center Scope: The study was conducted at a single hospital, and the results should be validated across multiple centers.
  2. BMI Constraints: The study excluded obese patients. Since obesity significantly increases the risk of airway collapse and hypoxia under sedation, future research is needed to see if HFNC provides the same level of protection for this higher-risk population.

Overall, the paper makes a strong case for HFNC as the new "gold standard" for oxygenation during invasive bronchoscopic procedures under deep sedation.

Summary updated

Abstract

https://www.chictr.org.cn, identifier ChiCTR2400085320.
BibTeX
@inproceedings{yue2025clinical,
  author = {Fangli Yue and Xinyuan Shi and Huan Zhang and Shui Yu and Min Fu and Yaxin Wei and Hongyi Xiao and Yuanyuan Zhong and Fanceng Ji and Peihe Nie},
  title = {{Clinical observations of high-flow nasal cannula oxygenation in endobronchial ultrasound-guided transbronchial needle aspiration: a randomized controlled study}},
  booktitle = {Frontiers in Medicine},
  year = {2025},
  doi = {10.3389/fmed.2025.1634020},
}
Figure